Novo Holdings A/S’s Protagonist Therapeutics PTGX Stock Holding History

Novo Holdings A/S’s Portfolio PTGX Stock Details PTGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-600,010	Closed	-$26.9M	–	53
2021 Q2	$26.9M	Sell	600,010 -267,714	-31%	-$8.84M	1.19%	21
2021 Q1	$22.5M	Hold	867,724	–	–	0.93%	22
2020 Q4	$17.5M	Buy	867,724 +73,355	+9%	+$1.58M	0.75%	25
2020 Q3	$15.5M	Sell	794,369 -29,800	-4%	-$559K	0.77%	20
2020 Q2	$14.6M	Buy	824,169 +126,270	+18%	+$1.58M	0.94%	18
2020 Q1	$4.93M	Buy	697,899 +218,825	+46%	+$1.64M	0.33%	24
2019 Q4	$3.38M	Hold	479,074	–	–	0.22%	25
2019 Q3	$5.75M	Buy	479,074 +455,173	+1,904%	+$5.74M	0.99%	18
2019 Q2	$289K	Buy	+23,901	New	+$264K	0.04%	29

Other funds holding PTGX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Novo Holdings A/S's PTGX Position: Q3 2021 in Review

Novo Holdings A/S sold out of Protagonist Therapeutics (PTGX) in Q3 2021, closing a stake of 600,010 shares — an estimated $26.9M sold.

Novo Holdings A/S first reported a position in PTGX in Q2 2019 and held it in 9 quarters. The position peaked at $26.9M in Q2 2021. 132 funds tracked by Wall St. Rank hold PTGX as of Q3 2021.

Novo Holdings A/S reported no remaining Protagonist Therapeutics position as of Q3 2021 after selling out during the quarter.
Novo Holdings A/S sold 600,010 Protagonist Therapeutics shares in Q3 2021, an estimated $26.9M.
Novo Holdings A/S first reported a position in Protagonist Therapeutics in Q2 2019 and held it in 9 quarters.
Novo Holdings A/S's Protagonist Therapeutics position peaked at $26.9M in Q2 2021.
132 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q3 2021.

Based on Novo Holdings A/S's 13F filing for Q3 2021, filed 15 Nov 2021.